PHVS
Pharvaris NV
NASDAQ · Healthcare · Biotechnology · NL
$36.37
−4.29%Sep 8, 2026, 11:43 UTC
Pharvaris N.V. announced positive topline results from the pivotal Phase 3 CHAPTER-3 study of deucrictibant XR for the prevention of hereditary angioedema attacks, meeting the primary endpoint with an 83% reduction in mean monthly attack rate versus placebo.
Aug 12, 2026, 10:50 UTC
Pharvaris announced its financial results for the second quarter ending June 30, 2026, and provided a business update.
Source:Jul 6, 2026, 10:50 UTC
The U.S. FDA accepted Pharvaris's New Drug Application for deucrictibant IR for on-demand treatment of hereditary angioedema attacks.